Get the Daily Brief
Latest Biotech News
Exact Sciences Launches Multi-Cancer Early Detection Test Cancerguard
Exact Sciences launched Cancerguard, a liquid biopsy test designed to detect signals from 50 different cancer types, expanding beyond established screenings for breast, lung, and colorectal...
New FDA Guidance Spurs Non-Opioid Chronic Pain Drug Development
The FDA issued draft guidelines aimed at encouraging development of non-opioid therapies for chronic pain, outlining expectations for clinical trial design and broad indications covering multiple...
Landmark Lasker Awards Honoring Cystic Fibrosis and Protein Biology Advances
The 2025 Lasker Awards recognized breakthroughs in cystic fibrosis treatment and protein science. Researchers including Michael Welsh received the Clinical Medical Research Award for pioneering...
Capsida Pauses Gene Therapy Trial After Patient Death
Capsida Biotherapeutics temporarily halted its Phase 1/2 clinical trial for a gene therapy targeting a rare neurodevelopmental disorder after the death of its first treated patient. The biotech is...
Merck Ends UK Research Operations, Cancels £1.3B London Lab
Merck announced the discontinuation of its research operations in the United Kingdom, including the cancellation of a planned £1.3 billion R&D center in London. The decision reflects ongoing...
AI Advances Drug Discovery: Harvard’s PDGrapher Predicts Therapeutic Targets
Harvard researchers developed PDGrapher, an AI-driven model that predicts combinations of therapeutic targets capable of reversing disease states at the cellular level. Unlike traditional...
Novartis Acquires Tourmaline Bio for $1.4B, Expanding Heart Drug Pipeline
Novartis announced the $1.4 billion acquisition of Tourmaline Bio, gaining rights to pacibekitug, a Phase 3-ready anti-IL-6 antibody targeting systemic inflammation in atherosclerotic...
Merck Pulls Out of UK as Life Science Investment Warnings Grow
Merck has decided to halt all research operations in the United Kingdom and cancel plans for a $1.3 billion drug discovery lab in London, citing insufficient progress and an unfriendly environment...
Johnson & Johnson Secures FDA Approval for Bladder Cancer Drug-Device Combo
Johnson & Johnson received FDA approval for Inlexzo, a drug-device combination delivering gemcitabine directly into the bladder to treat Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle...
Novartis Acquires Tourmaline Bio for $1.4 Billion Heart Disease Drug
Novartis agreed to acquire Tourmaline Bio for approximately $1.4 billion to obtain pacibekitug, a Phase 3-ready anti-IL-6 monoclonal antibody targeting inflammation in atherosclerotic...
LB Pharmaceuticals Raises $285M in Nasdaq IPO for Schizophrenia Drug
LB Pharmaceuticals successfully raised $285 million in its initial public offering on Nasdaq, marking the largest biotech IPO in over six months. The company plans to advance LB-102, an oral...
AI Model PDGrapher Identifies Disease-Reversing Therapeutic Targets
Researchers at Harvard Medical School developed PDGrapher, an artificial intelligence model that predicts treatments capable of reversing disease states in cells by identifying gene targets to...
Small Cell Lung Cancer Forms Functional Synapses with Neurons to Drive Growth
Groundbreaking studies reveal that small cell lung cancer (SCLC) cells integrate into neural circuits by forming active synaptic connections with neurons both within primary lung tumors and brain...
Sophont AI Raises $9.2M for Multimodal Medical Data Foundation Models
Sophont AI secured $9.2 million in funding to develop foundational AI models capable of analyzing diverse specialized medical data types. The company aims to create open-source, multimodal AI...
Lucid Diagnostics Raises Nearly $27M in Public Stock Offering
Lucid Diagnostics closed a public offering that raised $26.9 million, increasing its cash runway to support commercialization efforts for its EsoGuard test, a DNA methylation assay designed to...
New Non-Neutralizing Antibody Cocktail Shows Broad Protection Against Flu
Jackson Laboratory scientists developed a cocktail of non-neutralizing antibodies targeting influenza A virus (IAV) that demonstrated protection across nearly all tested flu strains, including...
University of Minnesota Receives $3.3M NIH Grant for Congenital CMV Study
The University of Minnesota Medical School secured a $3.3 million NIH grant to conduct a comprehensive, five-year longitudinal study focused on infants born with congenital cytomegalovirus (cCMV)...
Novartis Acquires Tourmaline Bio for $1.4 Billion to Boost Heart Drug Pipeline
Novartis has agreed to acquire clinical-stage biotech Tourmaline Bio for approximately $1.4 billion, obtaining rights to the anti-IL-6 monoclonal antibody pacibekitug aimed at treating...
Johnson & Johnson Secures FDA Approval for Bladder Cancer Drug-Device Therapy
Johnson & Johnson received U.S. Food and Drug Administration approval for Inlexzo, a drug-device combination that delivers gemcitabine intravesically to treat Bacillus Calmette-Guérin unresponsive...
LB Pharmaceuticals Raises $285 Million in Major Biotech IPO Focused on Schizophrenia Drug
LB Pharmaceuticals raised $285 million from its initial public offering on Nasdaq, marking the largest biotech public offering in over six months. The company plans to advance LB-102, an oral...